• Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000
• The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world’s first mass spectrometer-based explosive trace detectors (“ETD”), to customers in Romania
• Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp.
• The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in 2024 to $9.17 billion by 2029

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for the three months ended December 31, 2023 (“Q2 2024”).

The company recorded a 512% jump in its year-to-date (“YTD”) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM) explosive trace detectors (“ETDs”) to customers in Romania, which the company, through 1st Detect Corp., successfully delivered on (https://ibn.fm/nh80b).

The subsidiary 1st Detect develops, manufactures, and sells mass-spectrometer-based trace detectors – including the TRACER 1000(TM), the world’s first mass spectrometer-based ETD – for use in the security and detection markets. It is one of Astrotech’s wholly owned subsidiaries formed to explore and capitalize on opportunities in disparate markets. The other subsidiaries include Astrotech Technologies Inc, AgLAB Inc., Pro-Control Inc., and BreathTech Corp.

A recent SNS Insider article (https://ibn.fm/6nCuS) confirms that “the Explosive Trace Detection Market is witnessing significant growth driven by increasing security concerns, particularly in transportation, critical infrastructure, and public spaces”.  Specifically, it indicates: “The Explosive Trace Detection Market, valued at USD 1137.50 million in 2022, is projected to achieve a significant milestone, reaching USD 2250.60 million by 2030.” This market is yet another fast-growing and important opportunity for 1st Detect and the superior mass spectrometry technology it offers. The article continues that “there is a growing demand for advanced ETD systems that offer higher sensitivity, faster detection times, and improved ease of use”, the very capabilities that 1^st Detect represents. In particular, 1st Detect holds an exclusive AMS Technology license from ATI for air passenger and cargo security applications.

For its part, AgLAB has developed a mass-spectrometer-based chemical analyzer, the AgLAB 1000 series, and the AgLAB Maximum Value Process(TM) (“AgLAB MVP for use in botanical distillation and specifically, the hemp and cannabis sectors. AgLAB uses its proprietary mass spectrometry instrumentation on the manufacturing floor to test and analyze distilled cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oils quickly, easily, and continually, providing immediate information that not only maximizes potency but also improves the ending weight yields of every batch. According to AgLAB’s analysis, its mass spectrometers improve yields by an average of 34% (https://ibn.fm/OI897).

The U.S. cannabis market, which combines the recreational cannabis, medical cannabis, and therapeutic cannabis segments, is expected to experience significant growth in the coming years, according to Statista, reaching a projected $39.85 billion in revenue in 2024 and $67.15 billion by the end of 2028. The market is projected to grow at a CAGR of 13.93% during this forecast period (https://ibn.fm/pE5aV). Globally, the cannabis market is projected to reach revenue of $60.79 billion in 2024 and $102.90 billion by 2028, representing a CAGR of 14.06% (https://ibn.fm/nVjAS).

Beyond the U.S. cannabis and cannabinoids markets, Astrotech is positioned to capitalize on and benefit from the growth in the global mass spectrometry market, which is expected to grow from an estimated $6.77 billion in 2024 to $9.17 billion by 2029, representing a CAGR of 6.25%. “One of the major driving factors for the growth of the mass spectrometry market is the technological advancements in mass spectrometer devices,” wrote Mordor Intelligence in its report (https://ibn.fm/XmFDa).

Pro-Control subsidiary is expected to benefit from the global industrial automation and control systems market that is valued at USD 172.26 billion in 2022 with a compound annual growth rate (“CAGR”) of 10.5% from 2023 to 2030. The Pro-Control 1000(TM) mass spectrometer is designed to measure, test, and increase efficiencies in the chemical manufacturing processes.

Pro-Control MVP(TM) uses mass spectrometry instrumentation to monitor and control the fractional distillation of bulk chemicals using real-time in-process samples. “The Pro-Control subsidiary was launched late Q2 2024, and we look forward to introducing Pro-Control to chemical manufacturers who are using all types of distillation,” said Thomas B. Pickens, III, Astrotech’s Chairman, CEO, and CTO.

The BreathTech subsidiary is continuing its development of a breath analysis device that can provide early detection of lung diseases so that targeted antibiotics can be administered within minutes vs. days under current lab conditions. “The early BreathTech work was focused on COVID, but as vaccines were introduced and the effect of the disease outbreaks diminished, we have expanded our breath work to include other lung diseases that would benefit from early identification,” said Mr. Pickens.

The BreathTech subsidiary is continuing its development of a breath analysis device that can to provide early detection of lung diseases so that targeted antibiotics can be administered within seconds vs. days under current lab conditions. “The early BreathTest work was directed exclusively to COVID, but as the vaccines too effect and the disease outbreaks diminished, we have expanded our breath work to include other lung diseases that would benefit from early identification. The testing of these diseases is ongoing and we remain optimistic over our most recent results,” said Mr. Pickens.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

• Sigyn’s common stock, temporarily trading under the ticker symbol “SIGYD”, is set to revert back to its historic symbol “SIGY” on February 29, 2024.
• The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that target to overcome clearly defined limitations in global health.
• During 2023, Sigyn expanded its line-up of medical technologies designed to enhance the benefit of cancer therapies. The company’s cancer treatment pipeline now includes ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM).  
• The company believes the successful clinical advancement of Sigyn Therapy(TM) to treat pathogen-associated conditions beyond the reach of drugs, may offer a strategic competitive advantage within the dialysis industry.

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released its year-end 2023 financials and additionally disclosed the completion of a 1-for-40 reverse split of its common stock was implemented on January 31, 2024. As a result of this split, Sigyn’s common stock will trade under the ticker symbol “SIGYD” for 20 business days and revert to trading under its historic symbol “SIGY” on February 29, 2024.

According to the annual report filed by the company for the year ending December 31, 2023, Sigyn Therapeutics expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn Therapy(TM) have been identified. Sigyn Therapy(TM) is a novel blood purification technology to treat pathogen-associated conditions that are beyond the reach of drugs. (https://ibn.fm/ppTQT).

Sigyn Therapeutics is developing innovative medical technologies to address critical healthcare challenges. The company’s technologies show promise in improving patient outcomes across various medical conditions, presenting significant market opportunities in the healthcare sector.

Sigyn created each of its technologies with two prerequisites in mind:

1. The technology must overcome a clearly defined limitation in healthcare
2. The technology’s successful clinical advancement would offer a potential competitive advantage within an established therapeutic segment

Sigyn Therapy(TM) aims to treat pathogen-associated inflammatory conditions, including drug-resistant viral and bacterial infections, endotoxemia, and sepsis, which is a leading cause of hospital deaths in the US.  The novel blood purification technology is deployed on dialysis machines, and has been demonstrated to remove a broad-spectrum of relevant therapeutic targets human blood plasma.

The company believes the successful clinical advancement of Sigyn Therapy(TM) could offer a strategic competitive advantage within the dialysis industry. First-in-human studies call for the enrollment of dialysis dependent end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation. These are untreatable conditions associated with cardiovascular disease, a leading cause of ESRD patient deaths. Endotoxemia and inflammation also underlie other common causes of ESRD mortality, including viral and bacterial infections that induce sepsis.

A strategy that extended the lives of ESRD patients may be of considerable value to the dialysis industry when considering that more than 550,000 individuals suffer from ESRD in the United States alone. (https://ibn.fm/lmDib).

The ImmunePrep(TM) platform introduces a strategy to enhance the performance of immunotherapeutic antibodies through the elimination of circulating decoys that sequester or block cancer treatment antibodies from reaching their intended tumor cell targets.   While more than 1,000 therapeutic antibodies are being evaluated in human studies, Sigyn believes the ImmunePrep(TM) platform establishes the first strategy to eliminate the circulating decoys that limit the benefit of these highly valued drug agents.

ChemoPrep(TM) and ChemoPure(TM) are designed to overcome a delivery limitation and reduce toxicity of chemotherapy. ChemoPrep(TM) reduces the circulating presence of interference factors that inhibit chemotherapy from being delivered to intended cancer cell targets, while ChemoPure(TM) eliminates off-target chemotherapy to reduce patient toxicity and minimize organ damage.

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

• Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market
• The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes
• This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under Nasdaq rules – per share yielded approximately $3.6 million in gross proceeds. This was offered by the company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-262402), and it opens Lexaria to important new opportunities for the 2024 calendar year (https://ibn.fm/SrGcx).

Most notably, Lexaria intends to use the net proceeds from this offering for research and development (“R&D”) studies, and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/oo58J).

In 2023, Lexaria laid down the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose of Rybelsus that had been processed with DehydraTECH (TM) processing technology enhancements.

“Frankly, the results surprised us with their level of positivity,” noted Mr. Bunka.

“It was found that DehydraTECH processing: delivered a statistically-significant higher proportion of the semaglutide, and did so more quickly (very typical of results for our technology); reduced the quantity and severity of unwanted side effects; and had a statistically-significant impact on blood sugar in general and much more effectively after eating a meal, than did Rybelsus,” he added.

These results inspired the confidence of Lexaria’s team. In addition, the FDA’s recognition of GLP-1 drugs, having offered approvals as recently as 2021 and 2022 due to its health benefits, incentivized Lexaria to double down on this specific study. Consequently, the $3.6 million could not have come at a better time. Mr. Bunka and the rest of Lexaria’s management are optimistic that with this focus, the team’s hard work will prove its worth this year.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Correlate Energy, a publicly traded distributed energy solutions company, just announced its strategic partnership with Carbonsight, an online decarbonization planning tool
• With the partnership, Correlate will empower building portfolio owners with the tools and resources that allow them to make easier informed decisions toward decarbonization
• Move also complements Carbonsight’s mission of providing businesses with financially viable and environmentally sustainable solutions

Correlate Energy (OTCQB: CIPI), a publicly traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation, just announced its strategic partnership with Carbonsight (by Autocase). This move brings together Carbonsight’s cutting-edge decarbonization planning software and Correlate’s expertise in developing and financing renewable and clean energy projects, together helping businesses transition to a low-carbon future (https://ibn.fm/YlIUO).

“By combining Carbonsight’s advanced decarbonization planning software with Correlate’s expertise in developing and financing energy projects, we are creating a powerful synergy that empowers businesses to navigate the transition to a low-carbon future with confidence,” noted Todd Michaels, Correlate’s CEO.

Carbonsight is an online decarbonization planning tool specifically designed for real estate portfolios. It facilitates the development of building and portfolio plans to achieve carbon reduction targets. This allows building portfolio owners to organize pertinent data, quantify prospective CO2-reducing solutions, and visualize carbon reduction scenarios to achieve emission reduction goals.

With the strategic partnership, Correlate will get to empower building portfolio owners with the tools and resources that would allow them to make informed, impactful decisions that have positive economic benefits and create clear plans towards decarbonization. More importantly, it will complement Carbonsight’s mission of providing businesses with financially viable and environmentally sustainable solutions.

“We are thrilled to join forces with Correlate in this strategic partnership,” noted John Williams, Carbonsight’s CEO.

“Together, we offer building owners a comprehensive and integrated solution for decarbonization planning through implementation, making the journey towards sustainability more seamless and impactful,” he added.

This partnership marks a great start to the year for Correlate. It also serves as a testament to its commitment to maintaining the momentum gained in the previous year, having closed the year with the commissioning of American Tire Distributors’ (“ATD”) Huntersville, North Carolina headquarters, as well as the commissioning of a solar project at Continental Envelope’s Geneva, Illinois manufacturing plant earlier in the year. It further shows its commitment to creating shareholder value, even as it pushes to assert its position as a leader in the market.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Activist investors target underperforming companies with an eye toward implementing agendas to maximize shareholder value
• Efforts by the SEC to limit activist interventions include proposals to shorten Schedule 13 filing deadlines, mandate amendments within a day of significant changes, and prevent shareholders from interfering with a company’s pro-ESG initiatives
• Activist investors tackle ongoing challenges by staying on top of emerging trends, adopting best practices, and forming strategic alliances
• DealFlow Events presents an unparalleled networking and learning opportunity: The Activist Investor Conference on March 21, 2024, in New York City
• Like all DealFlow events, this conference promises to deliver. The event features 20+ experts discussing topics covering value investing strategies, legal issues, corporate relations, and international opportunities

Activist investors remain a force to be reckoned with. They target companies perceived to be underperforming or inefficient and implement strategies to maximize shareholder value.

That’s why they’re also called value investors.

Indicators of underperformance that grab their attention include stagnant stock prices, low profitability, inefficient resource utilization, governance deficiencies, regulatory scrutiny, and operation in industries undergoing significant disruption.

A recent example is Disney, where activist investors are leveraging their influence to alter the company’s strategic direction and corporate governance. To boost content production for its Disney+ streaming service, shareholders pressured the company to redirect resources from its annual dividend toward streaming content. Value investors also advocated for changes in the Disney board composition and executive compensation structures.

Markets typically respond positively to activist involvement. A recent example is the acquisition of a stake in Salesforce by San Francisco-based ValueAct Capital Management. ValueAct’s involvement resulted in a 10% employee reduction at Salesforce and the appointment of its co-chief executive officer to the board. Salesforce shares turned around as a result of these interventions, surging by 57% during Q1-2023.

Value investing is also picking up speed in Europe. According to a recent survey of corporate executives and activist investors, activity surged last year with a notable increase in new players launching a record number of new public campaigns.

Attempts by the SEC to curb activist interventions include proposals to decrease initial Schedule 13 filing deadlines to five days and requiring amendments within a day of significant changes. The proposals also aimed to push filers to disclose derivative holdings and eliminate the requirement for investors to act in concert. Additional rules were suggested to prevent activist shareholders from obstructing a company’s pro-ESG initiatives.

Activist investors effectively tackle these challenges by staying on top of emerging trends, adopting best practices, and forming strategic alliances.

The Activist Investor Conference on March 21, 2024 in New York City is where investors, corporate governance experts, advisory firms, proxy solicitors, and board members will gather to gain insights and forge partnerships. This year’s event features 20+ experts presenting topics covering value investing strategies, legal issues, corporate relations, international opportunities and more.

As with all DealFlow Events, the Activist Investor Conference promises to deliver. Learn more and register.

Quant Strats invites thought leaders, c-suite representatives, and executives from all over the globe, for a flourishing debate and discussion on the key trends and changes in the industry, with a specific focus on real-life applications. The Quant Strats Conference, taking place March 12th, 2024, is the leading event for quantitative thought leaders, where you can network with a crowd of over 300 quant leaders to learn the latest market dynamics. Connect with over 50 speakers from reputed entities such as Goldman Sachs, Robeco, Point72, ADIA, and many more.

The Quant Strats summit provides a phenomenal platform for industry representatives to meet and network with a unique audience, gather informative data that gives them a competitive edge, as well as connect with leaders of great knowledge and connect. The event will host debates, presentations, and panels consisting of influential C-suite representatives who decide on the trends and actions that drive the industry.

Quant Strats has worked for the past 10 years to explore, research, and gather quantum data and investment opportunities for meaningful collaboration among the selling and buying sides of the industry. The topics of the agenda include:

• Determining the next source of alpha
• Finding new sources of data in a saturated marketplace
• Applying the new technologies of ML, AI, and NPL for investment and risk management
• Exploring, organizing, and employing actionable data for various purposes
• Synchronizing and streamlining different processes

As markets of North America and Europe return to normality, experts are on the lookout for the next source of Alpha and the relevant data for streamlining the processes. These quantitative leaders get together at the Quant Strats platform to understand ways of generating alpha, managing risks, and discovering the best opportunities that the markets have to offer.

To know more, please visit https://ibn.fm/2e3QR

• Some high-profile investors and street-level market watchers are expressing faith that the real estate market is rebounding from last year’s slump, and are loading their money into key properties they believe have serious growth potential
• Utah-based Diamond Lake Minerals Inc. is creating a “powerful parent umbrella company” that pairs quality real world assets, such as real estate, with a digital “STO” asset, using the pairing as a means of inspiring confidence among those wary of involvement in the digital sector
• DLMI has teamed with U.S. Securities and Exchange Commission (“SEC”)-registered digital asset exchange INX to offer desired security in terms of real regulation
• The company envisions a portfolio that spans numerous market sectors such as real estate, wireless technology, and entertainment, providing a vertical integration of subsidiaries that are mutually supportive and of meaningful quality to investors

In San Francisco, the epicenter of last year’s nationwide downturn in the commercial real estate market with a similar slump in housing, real estate agents are seeing signs of new life as open houses draw surging numbers of visitors and stronger YOY sales.

“Open house visitor numbers have surged, new listings coming on market have risen, the pipeline of coming listings is filling up faster than last year, and the number of homes going into contract has begun to climb,” Compass chief market analyst Patrick Carlisle told SFGATE this month (https://ibn.fm/fPoB3). “With dramatic improvements since October in interest rates, stock markets and consumer confidence, both buyers and sellers are re-engaging to a much greater degree, and the velocity of the market is rapidly accelerating.”

A former Warren Buffet apprentice tied to the Toronto-based Reichmann real-estate dynasty is casting high-profile bets on San Francisco’s office buildings, further demonstrating an emerging confidence in the market for 2024 (https://ibn.fm/9UeRP).

Salt Lake City-based Diamond Lake Minerals (OTC: DLMI) CEO Brian J. Esposito is also promoting the evergreen potential of real estate investing — in DLMI’s case, it’s through a strategy of fractional ownership, using security tokens as a confidence-boosting gateway to an asset class many investors would not otherwise be able to access.

“There’s been great wealth created by cryptocurrencies and other types of digital assets that don’t operate in a regulatory environment … but it scares me that there’s so much money out there that is not protected or regulated,” Esposito told Proactive Investors last month (https://ibn.fm/LmEoy). “In a regulated environment, you’d create a giant funnel of liquidity and access to capital that was not able to be accessed before because there was no such thing as blockchain technology.”

Esposito noted that a lot of commercial properties may be overvalued and struggling to gain loans from rebank financing, but may nonetheless have “the ability to earn and create value.” Through regulated security token offerings (“STOs”), the property could be opened up to financing from “millions of people around the world.”

For its security token offerings, DLMI has partnered with U.S. Securities and Exchange (“SEC”)-registered security token exchange INX to provide a strict framework governed by guidelines that U.S. regulators have established.

Diamond Lake currently acquires, creates, and builds value in an industry-agnostic selection of companies that can exist within a variety of sectors, including the musical arts, health care, media, and varied forms of entertainment. Those companies are each imbued with an STO, making it easier for seasoned investors to turn to real world assets, but then explore the attached digital asset realm as well. The growing potential for similar investment in real estate is clear.

“We’re going to create a powerful parent umbrella company that has tremendous assets on its balance sheet as we continue to build and grow. Wonderful subsidiaries that we identify as great targets for our shareholders,” Esposito told financial media outlet Benzinga in December (https://ibn.fm/JtX7N).

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Las Vegas-based mine-to-jewelry maker GEMXX Corporation is reporting a 600 percent YOY jump in product delivery values for the month of January
• The company produces iridescent Ammolite jewelry that it obtains from its own gem mines in Alberta and gold mines in British Columbia, controlling each step in its production chain with no long-term debt
• GEMXX entered the gold market during the past year, enjoying the precious metal’s stability and record prices amid outside economic fluctuations
• GEMXX is working to improve its valuation, anticipating S-K 1300 technical reports on four assets will further improve the company’s balance sheet

North American mining and jewelry-making company GEMXX (OTC: GEMZ) is reporting the latest evidence that last year’s gamble on the gold market has paid off, bringing the mine-to-market enterprise a remarkable 600 percent YOY increase in the value of its product deliveries.

Approaching the end of February, gold prices continued to hold steady above the $2,000 per ounce mark despite a stronger dollar and elevated U.S. Treasury yields (https://ibn.fm/0brY9), keeping the precious metal in record territory after a stellar increase over 2022 demand during the past year (https://ibn.fm/k1fTR).

GEMXX specializes in the mining of Ammolite, a rare, opal-like gemstone that is only found on the eastern slopes of the Rocky Mountains in Southern Alberta, and last year expanded into the mining of gold to complement the historical resources that undergird its jewelry production strategy.

On Feb. 13, the company reported product deliveries worth $1,051,374 at retail for the month of January, highlighting the success of GEMXX’s focus on operational efficiency and production of high-margin products.

“Our ability to achieve such significant deliveries is a clear indication of our competitive edge in this industry and our deep understanding of our customers’ needs,” CEO Jay Maull stated in the announcement of the company’s achievement (https://ibn.fm/QhDnv). “Our strategic investments in increasing proven resources are laying the foundation for sustainable long-term growth. … We are confident in our ability to not only meet but exceed our financial goals for the coming year.”

GEMXX plans to build on the year-opening report with further investments in exploration, drilling, surveys, geotechnical reporting, research and development, marketing strategies and expansion into new markets, the company states.

Its strategy is designed to further enhance shareholder value and increase the company’s strength.

GEMXX has $600 million in proven Ammolite reserves and $300 million in gold reserves, according to the company (https://ibn.fm/KD8gu). The company is pursuing S-K 1300 technical reports on four assets owned by GEMXX and Canadian exploration partner Crazy Horse Mining Inc. (CHMI), anticipating that recalculation of inferred mineral resources already owned but not represented on the balance sheet will improve the company’s balance sheet.

“Management feels GEMZ is significantly undervalued,” GEMXX President Richard Clowater stated in October (https://ibn.fm/0X86b). “As of Q3 2023, the company only reported $14.1 million for owned resources, but this value is only a fraction of what the company owns. We feel the Net Present Value could exceed ten times that amount once resources are confirmed by an independent expert.”

In November, the company reported it is planning to expand its Ammolite gemstone and jewelry production by 300 percent this year, supplying it through GEMXX’s shopping channel division (https://ibn.fm/XqPCt). Ammolite comes from the fossilized shells of ammonites, a group of large, extinct marine nautiluses that exhibit iridescent color qualities.

Because the company controls each stage of its production and has no long-term debt, it has a distinct competitive advantage over other players in the precious metals sector.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/tJa8C) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com/investors.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Sigyn Therapeutics Chairman and CEO James A. Joyce recently provided a letter to shareholders that discussed the company’s therapeutic opportunities, challenges, and decision-making processes
• The letter overviewed the company’s candidate technologies to enhance the performance of cancer therapies (ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM)), and provided an update on Sigyn Therapy(TM), an extracorporeal drug purification technology to address pathogen-associated conditions that are beyond the reach of drugs

James A. Joyce, the Chairman and CEO of development-stage medical technology company Sigyn Therapeutics (OTCQB: SIGYD, SIGY), recently discussed the company’s opportunities, challenges, and decision-making processes in a letter to shareholders (https://ibn.fm/wGTqS). The company is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health:

• The ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer
• ChemoPrep(TM) to enhance the targeted delivery of chemotherapy
• ChemoPure(TM) to reduce the toxicity of chemotherapy
• Sigyn Therapy(TM) to address pathogen-associated conditions that are beyond the reach of drugs

Sigyn Therapeutics designed the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer. Though highly valued, these antibodies are limited by poor delivery to cancer cell targets and as a result, most patients do not respond to therapy. Inhibiting the delivery of therapeutic antibodies are circulating decoys that display the binding site target of the antibody and can be highly prevalent in the bloodstream. As a result, a significant portion of an antibody dose can bind to circulating decoys instead of cancer cell targets.

“Amazingly, with more than 1,000 therapeutic antibodies being evaluated in human studies, there was no strategy to reduce the circulating presence of decoys that block the delivery of these drugs,” wrote Mr. Joyce. To fill this gap, Sigyn Therapy designed the ImmunePrep(TM) platform, whose implementation is based on a reverse decoy mechanism. This mechanism will leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that extract antibody decoys from the bloodstream before the normal delivery of the same therapeutic antibodies.

“We believe this reverse decoy mechanism will increase the availability of antibodies to interact with their intended targets, and simultaneously, ImmunePrep(TM) devices are expected to extract disease targets from the bloodstream to further improve patient benefit,” explained James. “Our regulatory strategy is initially directed toward the development of ImmunePrep(TM) products that incorporate market-cleared antibodies already demonstrated to be safe and effective in human studies.”

Beyond ImmunePrep(TM), the company’s patent-pending ChemoPrep(TM) and ChemoPure(TM) are designed to enhance chemotherapy delivery and reduce toxicity, respectively. With recent scientific publications revealing that less than 2% of a chemotherapy dose is delivered to tumor cell targets, Sigyn Therapeutics recognized the need to create ChemoPrep(TM) to enhance chemotherapy delivery and the deploy ChemoPure(TM) post chemo delivery to reduce treatment toxicity and organ damage through the elimination of off-target chemotherapy from the bloodstream. “A reduction in chemotoxicity may also alleviate treatment-related fatigue and temper the long-term health consequences associated with chemotherapy administration,” stated Joyce.

ChemoPrep(TM) is designed to “reduce the circulating presence of tumor-derived exosomes (cancer exosomes) that interfere with chemotherapy delivery and contribute to treatment resistance.” Against this backdrop, Sigyn Therapeutics designed ChemoPrep(TM) to reduce of the circulating presence of exosomes prior to the infused delivery of chemotherapy to a patient. The company’s goal is to improve the delivery of chemotherapy and do so with lower doses, which would further reduce drug toxicity.

The company’s lead product candidate, Sigyn Therapy(TM), was created to address pathogen-associated inflammatory disorders that are not addressed with drug therapies. Its treatment indications include community-acquired pneumonia, drug-resistant viral and bacterial infections, endotoxemia, and sepsis, the leading cause of hospital deaths in the United States.

“We believe the successful clinical advancement of Sigyn Therapy(TM) could offer a strategic competitive advantage within the dialysis industry. As such, the treatment protocol of first-in-human studies calls for the enrollment of dialysis-dependent end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation. These are untreatable conditions associated with cardiovascular disease, a leading cause of ESRD patient deaths,” explained Mr. Joyce.

Mr. Joyce also indicated that extending of lives of ESRD patients and reducing ESRD patient hospitalizations should be of considerable value to the dialysis industry.  To support first-in-human studies of ESRD patients, the company has drafted an Investigational Device Exemption (“IDE”) for submission to the U.S. Food and Drug Administration (“FDA”).

“In closing, we have created an expansive lineup of therapeutic candidates with support from industry colleagues and the steadfast dedication of our team. A team that is not naïve to the challenges of advancing medical devices through FDA. A team focused on building an enduring organization whose therapies save lives,” concluded Joyce.

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

• Arizona-based SenesTech has developed a portfolio of rodent birth control products as a very effective alternative to deadly poisons often used to control rat populations
• SenesTech’s most recent product rollout is a soft bait formulation of its Birth Control for Rats(TM) branded Evolve(TM), in response to pest management businesses that prefer solid baits to SenesTech’s initial liquid products
• The company recently announced a partner agreement with grain management market distributor Poppe Enterprises to stock Evolve(TM) at outlets in states from North Dakota to Kansas and Colorado, following on the heels of a similar agricultural distribution agreement with a global irrigation solutions company

From New Orleans (https://ibn.fm/MyxuC) to Michigan (https://ibn.fm/nBfPB), eastward to Massachusetts (https://ibn.fm/1sMU1), and across the Atlantic to Europe (https://ibn.fm/6lMiL), concerns about confronting rats in the world’s cities continue to occupy news reports. But rats cause even more damage in agriculture.

Rodent pest control enterprise SenesTech (NASDAQ: SNES) is based in Arizona has begun to establish a global reach for its innovative Birth Control for Rats(TM) products, and the company is expanding its operations within agricultural sectors where rodent predation may otherwise have costly effects on food markets.

On Jan. 29, SenesTech announced the signing of a distribution agreement with Poppe Enterprises LLC for the grain management market. Poppe Enterprises will be a stocking distributor for SenesTech’s Evolve(TM) soft bait in the outlets it serves in Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa, and Colorado, according to the announcement.

“We are partnering with a leader and innovator in grain management and pest control,” SenesTech President and CEO Joel Fruendt stated (https://ibn.fm/K4hrs). “Poppe Enterprises has a keen focus on innovation, safety, and sustainability, and a strong reputation in this substantial market. Their presence and market knowledge will mean immediate penetration of the Evolve product.”

SenesTech’s Evolve(TM) soft bait delivers a cottonseed oil formulation that inhibits fertility in both male and female rats, using a highly palatable and effective alternative to deadly poisons. While Evolve(TM) can also work in concert with poisons to stop rodents from breeding and then to eliminate the rodents altogether, poisons can’t be broadcast in agricultural settings and the use of traps has limited effectiveness.

SenesTech’s agreement with Poppe Enterprises follows close on the heels of its agreement with a global sustainable irrigation solutions company to introduce Evolve(TM) to a California dairy and almond growing customer, with an eventual expansion goal to other customers around the world (https://ibn.fm/RMAhh).

Evolve(TM) is the latest entry into SenesTech’s portfolio of rat fertility control products. The company’s liquid bait formulation ContraPest(R) was the first rat contraceptive registered with the U.S. Environmental Protection Agency (“EPA”) that affects both male and female rats, and the company remains unchallenged in that regard.

The introduction of Evolve(TM) in October marked a new era for the company in response to pest management businesses that prefer solid baits they’re already equipped to use, as opposed to liquid formulations that are used far less often.

Market analysts at Straits Research valued the global rodent control market size at $2.86 billion in 2022 with an anticipated CAGR of 6.19 percent between 2023 and 2031, when it is expected to reach $4.9 billion (https://ibn.fm/3tkW2). MarketsandMarkets analysts valued their estimates at $5.4 billion in 2022, with an expected CAGR of 5.8 percent through 2027 lifting the market to a $7.1 billion valuation by that year (https://ibn.fm/39cX6).

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES